


IN THE CLAIMS:

Claims 1-9 and 15-29 have been cancelled. Claim 10 has been amended. Claims 30-53 have been added. This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-9. (cancelled)

10. (currently amended) A method for inhibiting a kinase, comprising administering to an animal in need thereof an effective amount of a compound having the structure:



and pharmaceutically acceptable salts thereof,

wherein

A is selected from $-C(=O)-$, $-(CH_2)_{0-4}-$, $-C(=O)(CH_2)_{1-3}-$, $-(CH_2)_{1-2}O-$ and $-(CH_2)_{1-2}S-$;

B is selected from N and CH;

C is selected from $-C(=O)-$, $-C(=O)(CH_2)_{1-3}-$, $-(CH_2)_{0-3}-$, $-O-$, $-S-$, $-O-(CH_2)_{1-2}-$ and $-S(CH_2)_{1-2}-$;

D is selected from N and $C(R_4)$;

E is selected from $\begin{array}{c} -C(R_1)- \\ | \\ NHZ \end{array}$, $\begin{array}{c} -N- \\ | \\ Z \end{array}$ and $\begin{array}{c} -C-(R_1) \\ | \\ Z \end{array}$;
 $\begin{array}{c} -C(R_1)- \\ | \\ Z \end{array}$;

F is an optional carbonyl moiety;

R₁ and R₄ are independently selected from amino acid side chain moieties and derivatives thereof;

R₂ and R₂' represent one or more optional ring substituents individually selected from an amino acid side chain moiety and derivatives thereof, or R₂ taken together with C or Y forms a fused substituted or unsubstituted homocyclic or heterocyclic ring;

R₃ is selected from an amino acid side chain moiety and derivatives thereof, or taken together with C forms a bridging moiety selected from -(CH₂)₁₋₂-, -O- and -S-;

Y and Z represent the remainder of the molecule; and

any two adjacent CH groups of the bicyclic ring may form a double bond.

11. (original) The method of claim 10 wherein E is
$$\begin{array}{c} \text{---C---} (R_1) \text{---} \\ | \\ \text{NHZ} \end{array}$$
.


12. (original) The method of claim 10 wherein E is
$$\begin{array}{c} \text{---N---} \\ | \\ \text{Z} \end{array}$$
.

13. (original) The method of claim 10 wherein E is , with
$$\begin{array}{c} \text{---C---} (R_1) \\ | \\ \text{z} \end{array}$$
 the proviso that Z does not contain an -NH- moiety attached to the carbon atom bearing the R₁ substituent.


14. (original) The method of claims 10 wherein the kinase is a serine/threonine or tyrosine kinase.

15-29. (cancelled)

30. (new) The method of claim 10 wherein the compound has the structure:




31. (new) The method of claim 30 wherein the compound has the structure:




wherein X is a substituent and m = 0-4.

32. (new) The method of claim 30 wherein the compound has the structure:



33. (new) The method of claim 32 wherein the compound has the structure:



34. (new) The method of claim 10 wherein R₁ is an amino acid side chain moiety or derivative thereof.

35. (new) The method of claim 10 wherein R₂ is an amino acid side chain moiety or derivative thereof.

36. (new) The method of claim 10 wherein R₂ is hydrogen or a lower chain alkyl.

37. (new) The method of claim 10 wherein R₂ is methyl.

38. (new) The method of claim 10 wherein R₃ is an amino acid side chain moiety or derivative thereof.

39. (new) The method of claim 10 wherein R₃ is hydrogen or methyl.

40. (new) The method of claim 10 wherein Y is an amino acid.

41. (new) The method of claim 10 wherein Y is selected from a group consisting of Serine, Threonine, Tyrosine, and Histidine.

42. (new) The method of claim 10 wherein Z is an amino acid side chain moiety or derivative thereof.

43. (new) The method of claim 10 wherein Z is an unsubstituted or substituted lower chain alkyl, lower chain aryl or lower chain aralkyl moiety.

44. (new) The method of claim 10 wherein Z is an unsubstituted or substituted phenyl or benzyl.

45. (new) The method of claim 10 wherein Z is a monosubstituted phenyl or benzyl.

46. (new) The method of claim 10 wherein the compound is administered to the animal for treatment of cancer, angiogenesis, restenosis, adema, inflammation, asthma, and arthritis.

47. (new) The method of claim 46 wherein the compound is administered to the animal for treatment of cancer.

48. (new) The method of claim 10 wherein F is a direct bond.

49. (new) The method of claim 10 wherein F is a carbonyl moiety.

50. (new) The method of claim 10 wherein F-Y, taken together, is
—C(=O)H, —C(=O)OH, —C(=O)OR, —C(=O)NHR, —C(=O)CH₂X,
—CH(OH)CH=CHC(=O)H, —CH(OH)CH=CHC(=O)R, —CH(OH)CH=CHC(=O)OR,
—C(=O)CH=CHC(=O)R, —C(=O)CH=CHC(=O)OR, —CH(OH)C≡CC(=O)R,
—CH(OH)C≡CC(=O)OR, —CH(OH)CH=CHC(=O)NHR,

—CH(OH)CH=CHC(=O)NRR, —C(=O)CH=CHC(=O)NHR,
—C(=O)CH=CHC(=O)NRR, —CH(OH)C≡CC(=O)NHR or
—CH(OH)C≡CC(=O)NRR, wherein each occurrence of R is independently selected
from a straight chain or branched, cyclic or noncyclic, substituted or unsubstituted,
saturated or unsaturated lower chain alkyl, aryl or aralkyl moiety, and X is Cl, F, Br or I.

51. (new) The method of claim 10 wherein R₂ is not present.
52. (new) The method of claim 10 wherein R₂' is not present.
53. (new) The method of claim 14 wherein the kinase is selected from a
cyclic AMP-dependent protein kinase A, a protein kinase C, a mitogen-activated protein
kinase, or a calcium-dependent protein kinase.